Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Furuya

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Scientific Reports|January 28, 2022
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradicationMasato Nakai, Yoshiya Yamamoto, Masaru Baba, et al.
Cancer|August 16, 2019
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexiaSatoshi Hamauchi, Junji Furuse, Toshimi Takano, et al.
Plos One|March 1, 2021
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2019
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysisKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Pancreas|April 24, 2018
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1Yasunori Sato, Hideki Ueno, Tatsuya Ioka, et al.
Viruses|January 21, 2023
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis CNaoki Kawagishi, Goki Suda, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2019
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameterTakaaki Izumi, Takuya Sho, Kenichi Morikawa, et al.
Gastro Hep Advances|November 24, 2025
Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North StudyHiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, et al.
Journal of Gastroenterology|March 20, 2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapyGoki Suda, Koji Ogawa, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Scientific Reports|January 28, 2022
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradicationMasato Nakai, Yoshiya Yamamoto, Masaru Baba, et al.
Cancer|August 16, 2019
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexiaSatoshi Hamauchi, Junji Furuse, Toshimi Takano, et al.
Plos One|March 1, 2021
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2019
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysisKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Pancreas|April 24, 2018
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1Yasunori Sato, Hideki Ueno, Tatsuya Ioka, et al.
Viruses|January 21, 2023
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis CNaoki Kawagishi, Goki Suda, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2019
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameterTakaaki Izumi, Takuya Sho, Kenichi Morikawa, et al.
Gastro Hep Advances|November 24, 2025
Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North StudyHiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, et al.
Journal of Gastroenterology|March 20, 2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapyGoki Suda, Koji Ogawa, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Pageof 7